Article: New Start-up Enavail Applies Proprietary Particle Engineering Technologies To Increase Drug Solubility, Stability and Bioavailability.

Enavail to focus on the $80.2 Billion drug delivery market. Company's particle engineering technologies increase the bioavailability of poorly water-soluble drugs and stabilize proteinaceous compounds and peptides.

Visit the Enavail Booth #2612 at APPS Los Angeles

AUSTIN, Texas -- Particle engineering company Enavail announced today that it has obtained an exclusive license from The University of Texas at Austin for a portfolio of particle engineering technologies that will be utilized for pharmaceutical, biotechnology and nutraceutical applications. Enavail is an Emergent Technologies, Inc. (ETI) portfolio company, headed by Dr. Brian Windsor, President ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!